Avni Wellness is riding high on the recent ₹4 crore fundraise from marquee investors like diagnostics pioneer Dr. A. Velumani, experienced D2C operators Puru Gupta and Sreejith Moolayil, and impact-focused investor Somya Nigam. Sujata Pawar, Founder at Avni Wellness, explains to Viveka Roychowdhury how Avni Wellness is breaking the silos in women’s health, the expansion strategy, and why it was important to built it to same standard as medicines, using science-backed formulations, clinically validated ingredients, and transparent labelling
What is the background of Avni’s founders and why did you choose women’s health?
Avni Wellness was founded by myself and my husband Apurv. We both come from the healthcare sector, which gave us an uncomfortable front-row view of how women’s health has historically been deprioritised; not for lack of awareness but for lack of genuine product innovation. The category had largely been reduced to maternal care and sanitary hygiene, with little attention paid to the broader hormonal and nutritional needs of women across their lifetime.
That gap was the founding insight. If you understand how drugs are developed and distributed, and you see how little of that rigour has been applied to women’s everyday health products, it becomes difficult to look away. Avni was built to bring that same standard – science-backed formulations, clinically validated ingredients, transparent labelling to a category that had been underserved for too long. For us this was never purely a business decision. It was a structural problem we were positioned to solve.
Healthcare models have traditionally focused on infertility and pregnancy care, but there is now a realisation that there are many gaps in women’s health across her life span. How does Avni Wellness fit into this trend?
Avni Wellness was built on the fundamental belief that women’s health cannot be addressed in silos. Hygiene, nutrition, and hormonal care are deeply interconnected, yet most solutions in the market continue to treat them as separate categories. From the outset, Avni’s thesis has been that the menstrual cycle is not a five-day event but a continuous 28-day physiological process, and therefore, care, especially nutrition must align with the entire cycle, not just the bleeding phase. This perspective, once niche, is now gradually becoming mainstream.
At the same time, most brands tend to focus on women in their peak reproductive years, typically in their 20s and 30s. Avni, however, is deliberately building across life stages from adolescence to reproductive years, and into perimenopause and menopause. Its cycle nutrition portfolio, including PCOS care, iron replenishment, and calcium support, is designed to follow a woman’s hormonal journey rather than just her pregnancy journey. Importantly, Avni is also addressing the underpenetrated 40+ segment, where Indian women enter perimenopause earlier than global averages. With products spanning UTI care, vaginal health, and hormonal support, the brand is positioning itself to serve this segment as a natural extension of its existing ecosystem.
What does the recent fundraise signify and what will it help build?
The recent ₹4 crore fundraise is as much about strategic alignment as it is about capital. The investor mix itself reflects this bringing together a diagnostics pioneer like Dr. A. Velumani, experienced D2C operators such as Puru Gupta and Sreejith Moolayil, and an impact-focused investor like Somya Nigam through Bharat ke Super Founders. Each of these stakeholders contributes a unique layer of expertise, from distribution credibility and consumer brand scaling to deep understanding of rural ecosystems.
The capital will be deployed across three key areas. First, it will enable the scaling of Avni’s women-led micro-entrepreneur network, strengthening last-mile distribution across Bharat. Second, it will deepen the brand’s nutrition portfolio, expanding its science-backed offerings. Third, it will enhance digital and quick commerce capabilities to improve accessibility and consumer reach. Additionally, the raise allows Avni to systematically unlock the clinical channel partnering with gynaecologists and nutritionists through structured programmes, kits, and commission models turning high-trust networks into a scalable growth lever.
What are the expansion plans and business strategy ahead?
The ₹15 crore raise over the next 12 months is about building the infrastructure for scale, not just growing the top line. The strategy runs on two parallel tracks: deepening urban D2C and quick commerce where repeat purchase and retention are the key metrics, and aggressively expanding Bharat distribution through the Avni Sakhi women-led micro-entrepreneur network, which we see as our most defensible long-term moat.
On the product and R&D front, Avni is expanding into underserved but highly relevant categories such as perimenopause support, UTI care, vaginal microbiome health, cramp relief, and hormonal acne. These areas are closely linked to the menstrual cycle but remain largely unaddressed in India. The menstrual hygiene portfolio will also continue to evolve with improved materials, performance textiles, and broader SKU offerings across leak care. While an IPO is not an immediate priority, the focus over the next 12 months is on achieving proof of scale, particularly increasing the contribution of Bharat-led distribution which will position the company strongly for its next institutional funding round.
What differentiates Avni from competitors?
Avni’s key differentiator lies in its integrated ecosystem approach. While most players focus on a single category be it hygiene, supplements, or community Avni operates across all three, creating a more holistic solution for women’s health. This is further strengthened by its Bharat-focused distribution model, which is both a growth driver and a defensible moat that is difficult to replicate.
On the product side, Avni has introduced India’s first patented antimicrobial reusable pad, combining safety, sustainability, and affordability. Made with laboratory-tested organic cotton, the product is designed to be 100% leak-proof and reusable up to 100 times, making it both clinically and economically superior to disposable alternatives. In nutrition, offerings like its melt-in-mouth liposomal iron supplement provide enhanced absorption and improved compliance. At its core, the brand is built on trust anchored in a “by women, for women, via women” philosophy that extends beyond messaging into its supply chain and distribution model.
